Syndax reports high remission rates in frontline revumenib combination trials ahead of ASH 2026

PUBT · 18h ago
Syndax reports high remission rates in frontline revumenib combination trials ahead of ASH 2026
  • Syndax Pharmaceuticals will report revumenib and axatilimab data at the American Society of Hematology meeting, December 12-15, 2026, in New Orleans.
  • Accepted abstracts include 14 for revumenib, seven featuring oral presentations, and five for axatilimab.
  • Updated frontline revumenib combination studies showed encouraging remission, clearance of measurable residual disease and survival outcomes in newly diagnosed acute myeloid leukemia.
  • Long-term axatilimab findings suggest potential for prolonged clinical benefit in relapsed or refractory chronic graft-versus-host disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9869911) on November 04, 2026, and is solely responsible for the information contained therein.